Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Melero I., Reis B., Rusterholz C., Epp A., Kratochwil NA., Wu C., Hettich M., Kazantzidis G., Rieder N., Schwalie PC., Badillo S., Kumpesa N., Thommen A., Vugts DJ., Moreno V., Lostes Bardaji J., Alvarez EC., de Andrea CE., Spanggaard I., Lee DH., Spicer J., Thistlethwaite F., Oh D-Y., Hollebecque A., Cirovic O., Symeonides SN.

DOI

10.1038/s43018-026-01157-8

Type

Journal article

Publisher

Springer Science and Business Media LLC

Publication Date

2026-05-01T00:00:00+00:00

Permalink More information Close